Erratum to: Tetraspanin CD63 acts as a pro-metastatic factor via β-catenin stabilization (Int J Cancer., (2015), 136, 10, (2304-2315), 10.1002/ijc.29296);Tetraspanin CD63 acts as a pro-metastatic factor via β-catenin stabilization

International Journal of Cancer

Volumn 136, Issue 10, 2015, Pages 2304-2315

  Seubert, Bastian ^a   Cui, Haissi ^a   Simonavicius, Nicole ^b   Honert, Katja ^a   Schäfer, Sandra ^a,c,d   Reuning, Ute ^b   Heikenwalder, Mathias ^b   Mari, Bernard ^c,d   Krüger, Achim ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d CNRS   (France)

Author keywords

beta catenin; cancer; CD63; E cadherin; epithelial mesenchymal transition (EMT); GSK3; mesenchymal to epithelial transition (MET); metastasis; PI3K; tetraspanin

Indexed keywords

BETA CATENIN; CD63 ANTIGEN; GELATINASE A; GLYCOGEN SYNTHASE KINASE 3BETA; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; CD63 PROTEIN, HUMAN; CD63 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GASTRIC CANCER CELL LINE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL LINE; METASTASIS; METASTASIS INHIBITION; MMP 2 GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIAN CANCER CELL LINE; PAI 1 GENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD63; BETA CATENIN; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION;

EID: 84924311392     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30237     Document Type: Erratum

References (49)

1. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
2. Thiery JP,. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
3. Thiery JP, Acloque H, Huang RYJ, et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
4. Kalluri R, Weinberg RA,. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-8.
5. Brabletz T,. To differentiate or not-routes towards metastasis. Nat Rev Cancer 2012; 12: 425-36.
6. Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-4.
7. Kimelman D, Xu W,. β-Catenin destruction complex: insights and questions from a structural perspective. Oncogene 2006; 25: 7482-91.
8. Zöller M,. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009; 9: 40-55.
9. Hemler ME,. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005; 6: 801-11.
10. Levy S, Shoham T,. Protein-protein interactions in the tetraspanin web. Physiology (Bethesda) 2005; 20: 218-24.
11. André M, Le Caer J-P, Greco C, et al. Proteomic analysis of the tetraspanin web using LC-ESI-MS/MS and MALDI-FTICR-MS. Proteomics 2006; 6: 1437-49.
12. Ridnour LA, Barasch KM, Windhausen AN, et al. Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation. PLoS ONE 2012; 7: e44081.
13. Rorive S, Lopez XM, Maris C, et al. TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas. Mod Pathol 2010; 23: 1418-28.
14. Lewis TB, Robison JE, Bastien R, et al. Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer 2005; 104: 1678-86.
15. Logozzi M, De Milito A, Lugini L, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS ONE 2009; 4: e5219.
16. Pols MS, Klumperman J,. Trafficking and function of the tetraspanin CD63. Exp Cell Res 2009; 315: 1584-92.
17. Radford KJ, Mallesch J, Hersey P,. Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer 1995; 62: 631-5.
18. Radford KJ, Thorne RF, Hersey P,. CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Biochem Biophys Res Commun 1996; 222: 13-8.
19. Radford KJ, Thorne RF, Hersey P,. Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. J Immunol 1997; 158: 3353-8.
20. Jang HI, Lee H,. A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med 2003; 35: 317-23.
21. Kwon MS, Shin SH, Yim SH, et al. CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung. Lung Cancer 2007; 57: 46-53.
22. Zhijun X, Shulan Z, Zhuo Z,. Expression and significance of the protein and mRNA of metastasis suppressor gene ME491/CD63 and integrin alpha5 in ovarian cancer tissues. Eur J Gynaecol Oncol 2007; 28: 179-83.
23. Jung KK, Liu XW, Chirco R, et al. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006; 25: 3934-42.
24. Cruz-Munoz W, Khokha R,. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008; 45: 291-338.
25. Toricelli M, Melo FH, Peres GB, et al. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer 2013; 12: 22.
26. Jung YS, Liu X-W, Chirco R, et al. TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLoS ONE 2012; 7: e38773.
27. Egea V, Zahler S, Rieth N, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling. Proc Natl Acad Sci USA 2012; 109: E309-16.
28. Hauser S, Bickel L, Weinspach D, et al. Full-length L1CAM and not its Δ2Δ27 splice variant promotes metastasis through induction of gelatinase expression. PLoS ONE 2011; 6: e18989.
29. Schelter F, Kobuch J, Moss ML, et al. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem 2010; 285: 26335-40.
30. Schambach A, Mueller D, Galla M, et al. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther 2006; 13: 1524-33.
31. Dumas JE, Platt MO,. Systematic optimization of multiplex zymography protocol to detect active cathepsins K, L, S, and V in healthy and diseased tissue: compromise between limits of detection, reduced time, and resources. Mol Biotechnol 2013; 54: 1038-47.
32. Krüger A, Soeltl R, Sopov I, et al. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 2001; 61: 1272-5.
33. He W, Tan R, Dai C, et al. Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/β-catenin signaling. J Biol Chem 2010; 285: 24665-75.
34. Doyle JL, Haas TL,. Differential role of β-catenin in VEGF and histamine-induced MMP-2 production in microvascular endothelial cells. J Cell Biochem 2009; 107: 272-83.
35. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-9.
36. Zavadil J, Böttinger EP,. TGF-β and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-74.
37. Krüger A,. Functional genetic mouse models: promising tools for investigation of the proteolytic internet. Biol Chem 2009; 390: 91-7.
38. Tsai JH, Donaher JL, Murphy DA, et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22: 725-36.
39. Ocaña OH, Cõrcoles R, Fabra A, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012; 22: 709-24.
40. Chambers AF, Groom AC, MacDonald IC,. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-72.
41. Nguyen DX, Bos PD, Massagué J,. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-84.
42. Dalerba P, Clarke MF,. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 2007; 1: 241-2.
43. Overall CM, Dean RA,. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev 2006; 25: 69-75.
44. Sordat I, Decraene C, Silvestre T, et al. Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells. Lab Invest 2002; 82: 1715-24.
45. Mantegazza AR, Barrio MM, Moutel S, et al. CD63 tetraspanin slows down cell migration and translocates to the endosomal-lysosomal-MIICs route after extracellular stimuli in human immature dendritic cells. Blood 2004; 104: 1183-90.
46. Skubitz KM, Campbell KD, Iida J, et al. CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils. J Immunol 1996; 157: 3617-26.
47. Rous BA, Reaves BJ, Ihrke G, et al. Role of adaptor complex AP-3 in targeting wild-type and mutated CD63 to lysosomes. Mol Biol Cell 2002; 13: 1071-82.
48. Yoshida N, Kitayama D, Arima M, et al. CXCR4 expression on activated B cells is downregulated by CD63 and IL-21. J Immunol 2011; 186: 2800-8.
49. Petersen SH, Odintsova E, Haigh TA, et al. The role of tetraspanin CD63 in antigen presentation via MHC class II. Eur J Immunol 2011; 41: 2556-61.